Neuracle Tech IPO: Pioneering China's Brain-Computer Interface Market

Neuracle Technology is on the cusp of a significant milestone, preparing to launch an Initial Public Offering (IPO) on the Shanghai Stock Exchange's Science and Technology Innovation Board. The company aims to secure approximately 2.5 billion yuan (around $345 million USD) through this listing, a move that would establish it as the first Chinese firm with brain-computer interface (BCI) as its primary focus to trade on the A-share market. This strategic financial maneuver underscores the growing global interest and investment in advanced neurotechnology.

Founded in 2011, Neuracle Technology has established itself as an early entrant and key player in China's nascent BCI sector. The company's dual approach encompasses both non-invasive BCI solutions, utilizing scalp-based electrodes, and more advanced invasive BCI systems requiring direct brain implantation. Its non-invasive portfolio already boasts over 20 developed products, including sophisticated brainwave monitoring and transcranial electrical stimulation devices, catering to a range of therapeutic and research applications.

A pivotal development for Neuracle Technology is the recent approval of its flagship invasive BCI product, the NEO-ONE SCI system. This device, designed to aid in the rehabilitation of hand motor function for patients with cervical spinal cord injuries, received Class III medical device certification from China's National Medical Products Administration (NMPA) in March 2026. This landmark approval marks the world's first commercialized invasive BCI medical device, positioning Neuracle at the forefront of clinical neurotechnology innovation.

The broader market context for BCI technology is one of rapid expansion and strategic importance. Recognized as a frontier technology alongside artificial intelligence, BCI is receiving significant governmental backing in China. The nation's Ministry of Industry and Information Technology explicitly identified BCI as a key future industry in its 2024 policy document, signaling a concerted effort to foster domestic innovation and competitiveness in this high-potential field. This supportive policy environment provides a fertile ground for companies like Neuracle Technology.

Despite its technological advancements and market potential, Neuracle Technology faces the inherent financial challenges of commercializing cutting-edge medical devices. While the company has demonstrated revenue growth, increasing from 75.21 million yuan in 2023 to 108 million yuan in 2025, its net losses have also widened considerably, reaching 230 million yuan in 2025. Currently, the bulk of its revenue, over 90%, is generated from its non-invasive BCI products, indicating that the high-margin invasive BCI segment is still in its early stages of market penetration and revenue generation.

The upcoming IPO represents a critical juncture for Neuracle Technology, providing the necessary capital to scale its operations, further develop its invasive BCI technologies, and navigate the complex path to widespread commercial adoption. Success in this endeavor would not only validate the company's vision but also pave the way for increased investment and development within China's rapidly evolving BCI ecosystem, potentially influencing global market dynamics in neurotechnology.